Framtiden sårvård med stor marknad är på väg till kommersialiseringsfas.
Redeye comments on the Q4 report from Bioservo. In total, a report without any surprises in our view...
Redeye gives its initial take of Paynova’s fourth-quarter report of 2021, which was slightly above o...
Redeye comments on Imint's Q4 report, which showed all-time net revenues and stable profitability.
Redeye comments on the Q4 report, which offered few surprises.
Vaisala’s Q4 topline was in line with our expectations, but earnings fell short due to declined marg...
Finnair’s Q4 report didn’t include that significant news.
Innofactor’s Q4 fell well short of our expectations as the company saw challenges relating to organi...
NoHo reported Q4 EBIT of EUR 6.7m, clearly above Infront consensus expectations.
Redeye comments on Zordix announcement that is Christina Seelye Appointed as New CEO.
Analyst Group har med Alltainer ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Ferroamp redovisar ett svalt fjärde kvartal präglat av global komponentsbrist och leveransstopp hos ...
DevPort levererar ett starkt fjärde kvartal och växer organiskt med hela 46 procent samtidigt som ma...
Analysguiden inleder bevakning av e-handelsbolaget Purefun Group.
Redeye maintains its positive view and valuation of Optomed.
Redeye comments on Nanexa's Q4 report and summarize our view of progress in 2021.
Fortsatt starkt momentum i ARR-tillväxt ARR uppgick till 111,8 mkr vilket motsvarar en tillväxt om 2...
Redeye comments on Scandion’s fourth quarter report for 2021, going into an important year for the c...
Redeye’s preliminary revisions suggest largely unchanged forecasts for 2022E and 2023E, as the stron...
Redeye returns with a more in-depth take on BONESUPPORT’s Q4-report following the conference call an...
